Addendum
Olaparib (breast cancer) - Addendum to Commission A19-57
Report documents
-
Addendum
Olaparib (breast cancer) - Addendum to Commission A19-57
Dossier assessment
Indication:
Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer
Result of dossier assessment:
Conclusion of dossier assessment A19-57 unchanged
Additional information
Federal Joint Committee (G-BA)
2020-01-16 A G-BA decision was published.
Project details
- Project no.
- A19-97
- Commission
- Commission awarded on 26.11.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed